Published in Br J Cancer on January 01, 1993
TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J (2005) 2.81
Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest (1993) 1.53
Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer (2000) 1.31
Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats. Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. J Clin Invest (1995) 1.31
Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg (2003) 1.28
Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest (1995) 1.09
Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer (2001) 1.03
Pharmacological interference with tissue hypercatabolism in tumour-bearing rats. Biochem J (1994) 0.88
l-carnitine and cancer cachexia: Clinical and experimental aspects. J Cachexia Sarcopenia Muscle (2011) 0.85
Muscle wasting in animal models of severe illness. Int J Exp Pathol (2012) 0.80
Day-night pattern of energy expenditure and body temperature in cachectic tumour-bearing rats. Br J Cancer (2000) 0.78
Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130). Br J Cancer (1995) 0.77
Rikkunshito Ameliorates Cancer Cachexia Partly through Elevation of Glucarate in Plasma. Evid Based Complement Alternat Med (2015) 0.75
Chromatography of amino acids on sulfonated polystyrene resins. J Biol Chem (1951) 21.20
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods (1984) 4.27
Tumors secreting human TNF/cachectin induce cachexia in mice. Cell (1987) 4.19
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Evidence for tumour necrosis factor/cachectin production in cancer. Lancet (1987) 3.66
Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med (1983) 3.49
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med (1992) 3.37
Raised serum levels of tumour necrosis factor in parasitic infections. Lancet (1986) 3.23
Arachidonic acid, prostaglandin E2 and F2 alpha influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem (1982) 2.59
Protein turnover in skeletal muscle. II. Effects of denervation and cortisone on protein catabolism in skeletal muscle. J Biol Chem (1969) 2.27
Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res (1987) 2.03
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol (1989) 1.99
Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest (1987) 1.95
Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest (1991) 1.88
Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J (1989) 1.82
Protein turnover with special reference to man. Q J Exp Physiol (1984) 1.75
Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res (1991) 1.74
Increased plasma interleukin-1 activity in women after ovulation. Science (1985) 1.70
The stimulation of protein degradation in muscle by Ca2+ is mediated by prostaglandin E2 and does not require the calcium-activated protease. J Biol Chem (1982) 1.70
Effects of systemic inhibition of prostaglandin production on protein metabolism in tumor-bearing rats. Am J Physiol (1989) 1.68
Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res (1991) 1.68
Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest (1988) 1.59
The history, properties, and biological effects of cachectin. Biochemistry (1988) 1.51
Cancer cachexia. JPEN J Parenter Enteral Nutr (1988) 1.48
Tumour necrosis factor in man: clinical and biological observations. Br J Cancer (1987) 1.46
THE EFFECT OF GLUCAGON ON NET SPANCHNIC BALANCES OF GLUCOSE, AMINO ACID NITROGEN, UREA, KETONES, ANS OXYGEN IN MAN. J Clin Invest (1964) 1.46
Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res (1991) 1.44
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A (1990) 1.34
Tumor necrosis factor-alpha is a potent ACTH secretagogue: comparison to interleukin-1 beta. Endocrinology (1989) 1.31
Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol (1986) 1.29
Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst (1988) 1.23
Effect of corticosterone treatment on muscle protein turnover in adrenalectomized rats and diabetic rats maintained on insulin. Biochem J (1982) 1.22
Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci U S A (1988) 1.20
Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology (1987) 1.20
Interleukin 1 affects glucose homeostasis. Am J Physiol (1987) 1.19
Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice. J Exp Med (1988) 1.16
Metabolic approaches to cancer cachexia. Annu Rev Nutr (1982) 1.15
Metabolic effects of tumour necrosis factor-alpha (cachectin) and interleukin-1. Clin Sci (Lond) (1989) 1.15
Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Res (1989) 1.13
Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. Biochem J (1987) 1.12
Tumor necrosis factor in children with malignancies. Cancer Res (1990) 1.09
Chronic TNF infusion causes anorexia but not accelerated nitrogen loss. Ann Surg (1989) 1.08
Cachectin/tumour-necrosis-factor production by cancer patients. Lancet (1985) 1.08
Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). Br J Cancer (1992) 1.06
Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res (1990) 1.04
Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. Cancer Res (1990) 1.03
Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. J Clin Invest (1988) 1.02
Contribution of elevated protein turnover and anorexia to cachexia in patients with hepatocellular carcinoma. Cancer Res (1990) 1.01
Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res (1988) 1.00
Are the catabolic effects of tumor necrosis factor mediated by glucocorticoids? Arch Surg (1990) 1.00
Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. Br J Cancer (1988) 0.99
Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. Cancer Res (1984) 0.98
Persistence of the hypertriglyceridemic effect of tumor necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. Cancer Res (1989) 0.97
Interleukin-1: biology, pathophysiology, and clinical prospects. Am J Med (1990) 0.96
Pathogenesis of cachexia in cancer. A review and a hypothesis. Cancer (1972) 0.93
Glucocorticoids and catecholamines as mediators of acute-phase proteins, especially rat alpha-macrofoetoprotein. Biochem J (1984) 0.90
Serum insulin and somatomedin levels in the tumour-bearing rat. Eur J Cancer (1975) 0.90
Cachectin activity in the serum of cachectic, tumor-bearing rats. Arch Surg (1989) 0.90
Close association of accelerated rates of whole body protein turnover (synthesis and breakdown) and energy expenditure in children with newly diagnosed acute lymphocytic leukemia. JPEN J Parenter Enteral Nutr (1987) 0.89
Increased whole-body protein turnover in sick children with newly diagnosed leukemia or lymphoma. Cancer Res (1983) 0.89
On the multiform relationships between the tumor and the host. Adv Cancer Res (1979) 0.87
Human recombinant interleukin-1 beta and -alpha, but not recombinant tumor necrosis factor alpha stimulate ACTH release from rat anterior pituitary cells in vitro in a prostaglandin E2 and cAMP independent manner. Neuroendocrinology (1988) 0.87
Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor. Cancer Res (1990) 0.87
Control of cell protein catabolism in rat liver. Effects of starvation and administration of cycloheximide. Biochem J (1982) 0.87
Skeletal muscle and whole body protein turnover in thyroid disease. Eur J Clin Invest (1988) 0.86
Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. Br J Cancer (1980) 0.85
Lipogenesis in tumour and host tissues in mice bearing colonic adenocarcinomas. Br J Cancer (1991) 0.85
Tumor-host wasting not explained by adrenal hyperfunction in tumor-bearing animals. J Natl Cancer Inst (1987) 0.83
Regulation of protein turnover versus growth state: ascites hepatoma as a model for studies both in the animal and in vitro. Arch Biochem Biophys (1987) 0.83
Amino acid metabolism in human cancer cachexia. Annu Rev Nutr (1990) 0.83
Influence of the Walker 256 carcinosarcoma on muscle, tumor, and whole-body protein synthesis and growth rate in the cancer-bearing rat. Cancer Res (1986) 0.83
Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia. Ann Surg (1987) 0.83
The concentrations of 6-keto-PGF1 alpha and TXB2 in plasma samples from patients with benign and malignant tumours of the breast. Prostaglandins (1985) 0.82
Regulation of B cell tolerance by macrophage-derived mediators: antagonistic effects of prostaglandin E2 and interleukin 1. J Immunol (1986) 0.81
Contribution of inert mass to experimental cancer cachexia in rats. J Natl Cancer Inst (1984) 0.80
Alterations in whole body, muscle, liver, and tumor tissue protein synthesis and degradation in Novikoff hepatoma and Yoshida sarcoma tumor growth studied in vivo. Cancer Res (1988) 0.80
Role of insulin in development of cancer cachexia in nongrowing sarcoma-bearing mice: special reference to muscle wasting. J Natl Cancer Inst (1987) 0.80
Regulation of thyrotropin secretion in rats bearing the Walker 256 carcinoma. Endocrinology (1981) 0.80
Aliphatic aldehydes inhibit the proliferative response of human peripheral blood lymphocytes to phytohemagglutinin and alloantigens. Chem Biol Interact (1987) 0.79
Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer Res (1989) 0.79
Sphingosine synergistically stimulates tumor necrosis factor alpha-induced prostaglandin E2 production in human fibroblasts. J Exp Med (1991) 0.79
Growth hormone and experimental cancer cachexia. J Natl Cancer Inst (1987) 0.78
Dietary control of protein turnover. Diabete Metab (1988) 0.77
In the rat, interleukin-1 alpha and -beta stimulate adrenocorticotropin and catecholamine release. Endocrinology (1989) 0.77
Monocytic production and plasma bioactivities of interleukin-1 and tumour necrosis factor in human cancer. Eur J Clin Invest (1988) 0.77
Relative competition of corticosterone, cortisol, cortisone, 11-dexycortisol and prednisolone with (1,2-3H)-cortisol in various protein-binding radioassay systems. Clin Chim Acta (1975) 0.76
Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression. Clin Exp Immunol (1991) 0.76
The correlation of body growth with diethylnitrosamine-induced hepatocarcinogenesis in relation to serum insulin and somatomedin-C. Carcinogenesis (1991) 0.76
Increased production of tumor necrosis factor by normal immune cells in a model of the humoral hypercalcemia of malignancy. Lab Invest (1990) 0.76
Supramaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis. Am J Physiol (1984) 2.33
Effect of microtubular or translational inhibitors on general cell protein degradation. Evidence for a dual catabolic pathway. Biochem J (1977) 1.93
Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis (1993) 1.80
Cancer cachexia: from experimental models to patient management. Curr Opin Clin Nutr Metab Care (2000) 1.54
Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest (1993) 1.53
Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer (2000) 1.31
Studies on the structure-bound sedimentabolity of some rat liver lysosome hydrolases. Biochem J (1971) 1.23
Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun (1999) 1.23
Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer (1994) 1.20
Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia (1994) 1.15
Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. Biochem J (1987) 1.12
Intracellular ionic variations in the apoptotic death of L cells by inhibitors of cell cycle progression. Exp Cell Res (1995) 1.12
Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest (2008) 1.11
Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest (1995) 1.09
Inhibition of basal protein degradation in rat embryo fibroblasts by cycloheximide: correlation with activities of lysosomal proteases. J Cell Physiol (1978) 1.07
Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). Br J Cancer (1992) 1.06
Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer (2001) 1.03
Structural equivalents of latency for lysosome hydrolases. Biochem J (1975) 1.02
Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta (2001) 1.02
Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets (2009) 1.01
Control of cell protein degradation. Changes in activities of lysosomal proteases. Biochim Biophys Acta (1977) 1.01
Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys (1993) 1.01
Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol (2001) 0.99
Altered pattern of lipid metabolism in patients with lung cancer. Oncology (1992) 0.98
Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett (1998) 0.97
Mice lacking TNFalpha receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death Differ (2003) 0.96
Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine (2002) 0.92
Cell protein degradation in cultured rat embryo fibroblasts. Suppression by vinblastine of the enhanced proteolysis by serum-deficient media. Biochim Biophys Acta (1976) 0.92
Differential segregation of human and hamster cathepsin D in transfected baby-hamster kidney cells. Biochem J (1991) 0.89
Pharmacological interference with tissue hypercatabolism in tumour-bearing rats. Biochem J (1994) 0.88
Melatonin and cortisol circadian secretion during ethanol withdrawal in chronic alcoholics. Chronobiologia (1994) 0.88
Changes induced by fasting and cycloheximide in the vacuolar apparatus of rat hepatocytes. A morphometric investigation. Boll Soc Ital Biol Sper (1979) 0.87
Skeletal muscle wasting in tumor-bearing rats is associated with MyoD down-regulation. Int J Oncol (2005) 0.87
Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem Biophys Res Commun (1996) 0.87
Control of cell protein catabolism in rat liver. Effects of starvation and administration of cycloheximide. Biochem J (1982) 0.87
Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model. Clin Sci (Lond) (1994) 0.86
Acute hemorrhagic pancreatic necrosis in mice: the activity of lysosomal enzymes in the pancreas and the liver. Am J Pathol (1980) 0.86
Effect of 4-Hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells. Free Radic Biol Med (1996) 0.86
Differentiation-dependent autophagy controls the fate of newly synthesized N-linked glycoproteins in the colon adenocarcinoma HT-29 cell line. Biochem J (1995) 0.85
On the structure-linked sedimentability of rat liver beta-N-acetylglucosaminidase. Biochim Biophys Acta (1971) 0.84
Prevention of cancer and cardiovascular diseases: a common strategy? Med Res Rev (1998) 0.84
Biochemical and structural changes of rat liver lysosomes by ethionine. Exp Mol Pathol (1975) 0.84
Lysosomal involvement in liver cell vacuolation by hypoxia. Br J Exp Pathol (1969) 0.84
Expression of protein kinase C beta1 confers resistance to TNFalpha- and paclitaxel-induced apoptosis in HT-29 colon carcinoma cells. Int J Cancer (2001) 0.84
Impaired macrophage phagocytosis of apoptotic neutrophils in patients with human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol (2002) 0.83
Regulation of protein turnover versus growth state: ascites hepatoma as a model for studies both in the animal and in vitro. Arch Biochem Biophys (1987) 0.83
Transformation by oncogenic ras-p21 alters the processing and subcellular localization of the lysosomal protease cathepsin D. J Cell Biochem (1999) 0.83
Clinical remission is associated with restoration of normal high-density lipoprotein cholesterol levels in children with malignancies. Clin Sci (Lond) (1995) 0.83
Differentiation-induced changes in the content, secretion, and subcellular distribution of lysosomal cathepsins in the human colon cancer HT-29 cell line. Cell Tissue Res (1997) 0.83
Tissue protein turnover during liver carcinogenesis. Carcinogenesis (1993) 0.83
Candida albicans and HIV-1 Infection. Cell Biochem Funct (2000) 0.82
Role of mitogen-induced calcium influx in the control of the cell cycle in Balb-c 3T3 fibroblasts. Cell Calcium (1995) 0.82
High levels of proteolytic enzymes in the ascitic fluid and plasma of rats bearing the Yoshida AH-130 hepatoma. Invasion Metastasis (1995) 0.82
Cloning and expression of two ornithine decarboxylase forms from HMOA cells. Biochem J (1995) 0.82
Purification and properties of cathepsin D from rat Yoshida ascites hepatoma AH-130. Biol Chem Hoppe Seyler (1988) 0.81
Mis-sorting of procathepsin D in metastogenic tumor cells is not due to impaired synthesis of the phosphomannosyl signal. Int J Cancer (1997) 0.81
Urine melatonin in alcoholic patients: a marker of alcohol abuse? J Endocrinol Invest (1991) 0.81
The direct effect of carbon tetrachloride on subcellular particles. Lab Invest (1966) 0.81
Altered intracellular processing and enhanced secretion of procathepsin D in a highly deviated rat hepatoma. Int J Cancer (1995) 0.81
Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Lett (1996) 0.81
Intracellular free iron and acidic pathways mediate TNF-induced death of rat hepatoma cells. Apoptosis (2005) 0.81
Expression and posttranslational fate of cathepsin D in HT-29 tumor cells depend on their enterocytic differentiation state. Cell Growth Differ (1997) 0.81
Apoptosis of L929 cells by etoposide: a quantitative and kinetic approach. Exp Cell Res (1996) 0.81
Is TNF really involved in cachexia? Cancer Invest (1997) 0.81
Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression. Curr Med Chem (2010) 0.80
Decreased expression of the high-mobility group protein T160 by antisense RNA impairs the growth of mouse fibroblasts. Biochimie (1997) 0.80
Suppression of the 'uncovering' of mannose-6-phosphate residues in lysosomal enzymes in the presence of NH4Cl. Eur J Biochem (1990) 0.80
Regulation of protein turnover versus growth state. Studies on the mechanism(s) of initiation of acidic vacuolar proteolysis in cells of stationary ascites hepatoma. Biochem J (1988) 0.80
Sustained calcium influx activated by basic fibroblast growth factor in Balb-c 3T3 fibroblasts. J Physiol (1995) 0.80
Stimulation of rat liver beta-galactosidase activity by ions. Biochem J (1975) 0.80
Potassium and calcium currents activated by foetal calf serum in Balb-c 3T3 fibroblasts. Biochim Biophys Acta (1992) 0.80
Two currents activated by epidermal growth factor in EGFR-T17 fibroblasts. Biochim Biophys Acta (1992) 0.80
Lysosomal hydrolase activities in the developing rat liver. Boll Soc Ital Biol Sper (1980) 0.79
Sex hormones and pituitary function in male epileptic patients with altered or normal sexuality. Epilepsia (1995) 0.79
Aliphatic aldehydes inhibit the proliferative response of human peripheral blood lymphocytes to phytohemagglutinin and alloantigens. Chem Biol Interact (1987) 0.79
Further experiments on the action of CCl-4 on lysosomes in vitro. Enzymologia (1965) 0.79
Human and hamster procathepsin D, although equally tagged with mannose-6-phosphate, are differentially targeted to lysosomes in transfected BHK cells. Cell Tissue Res (1998) 0.79
Control of protein degradation and growth phase in normal and neoplastic cells. Toxicol Pathol (1984) 0.79
Mechanisms of clofibrate-induced apoptosis in Yoshida AH-130 hepatoma cells. Biochem Pharmacol (2008) 0.79
The role of apoptosis in growing and stationary rat ascites hepatoma, Yoshida AH-130. J Pathol (1993) 0.79
Comparative studies on protein turnover regulations in tumor cells and host tissues: development and analysis of an experimental model. Toxicol Pathol (1986) 0.79
Protein turnover states of tumour cells and host tissues in an experimental model. Biomed Biochim Acta (1986) 0.79